| Literature DB >> 32012817 |
Robert Gajda1, Anna Klisiewicz2, Vadym Matsibora3, Dorota Piotrowska-Kownacka4, Elżbieta Katarzyna Biernacka2.
Abstract
The impact of ultramarathon (UM) runs on the organs of competitors, especially elite individuals, is poorly understood. We tested a 36-year-old UM runner before, 1-2 days after, and 10-11 days after winning a 24-h UM as a part of the Polish Championships (258.228 km). During each testing session, we performed an electrocardiogram (ECG), transthoracic echocardiography (TTE), cardiac magnetic resonance imaging (MRI), cardiac 31P magnetic resonance spectroscopy (31P MRS), and blood tests. Initially, increased cholesterol and low-density lipoprotein cholesterol (LDL-C) levels were identified. The day after the UM, increased levels of white blood cells, neutrophils, fibrinogen, alanine aminotransferase, aspartate aminotransferase, creatine kinase, C-reactive protein, and N-terminal type B natriuretic propeptide were observed. Additionally, decreases in hemoglobin, hematocrit, cholesterol, LDL-C, and hyponatremia were observed. On day 10, all measurements returned to normal levels, and cholesterol and LDL-C returned to their baseline abnormal values. ECG, TTE, MRI, and 31P MRS remained within the normal ranges, demonstrating physiological adaptation to exercise. The transient changes in laboratory test results were typical for the extreme efforts of the athlete and most likely reflected transient but massive striated muscle damage, liver cell damage, activation of inflammatory processes, effects on the coagulation system, exercise-associated hyponatremia, and cytoprotective or growth-regulatory effects. These results indicated that many years of intensive endurance training and numerous UMs (including the last 24-h UM) did not have a permanent adverse effect on this world-class UM runner's body and heart. Transient post-competition anomalies in laboratory test results were typical of those commonly observed after UM efforts.Entities:
Keywords: Cardiac 31P-MR spectroscopy; blood tests; echocardiography; electrocardiogram; magnetic resonance imaging; professional ultramarathon runner
Year: 2020 PMID: 32012817 PMCID: PMC7168911 DOI: 10.3390/diagnostics10020073
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Detailed weather condition in Łódź, Poland, during a 24-h UM competition according to Global Forecast System weather (API by AccuWeather, Inc., State College, Pennsylvania, USA).
Date, place, and type of medical tests.
| Days before or after the Run | Before Run | 1 Day after the Run | 2 Days after the Run | 10 Days after the Run | 11 Days after the Run |
|---|---|---|---|---|---|
| ECG | x | x | x | ||
| TTE | x | x | x | ||
| Blood tests | x | x | x | ||
| MRI | x | x | x | ||
| Cardiac 31P MRS | x | x | x |
ECG, electrocardiogram; TTE, transthoracic echocardiography; MRI, magnetic resonance imaging; 31P MRS, cardiac 31P magnetic resonance spectroscopy.
Summary results of blood tests.
| Parameters | Units | Before Run | 1 Day after the Run | 10 Days after the Run | Reference Values |
|---|---|---|---|---|---|
|
| |||||
| White blood cells | 109/L | 4 | ↑ 10.87 | 5.36 | 4.0–10.0 |
| Neutrophils | 109/L | ↓1.81 | ↑ 8.46 | 2.67 | 2.5–5.0 |
| Neutrophils (%) | % | 45.2 | ↑ 77.8 | 49.8 | 45.0–70.0 |
| Lymphocytes | 109/L | ↓ 1.22 | ↓ 1.18 | 1.74 | 1.5–3.5 |
| Lymphocytes (%) | % | 30.5 | ↓ 10.9 | 32.5 | 20.0–45.0 |
| Monocytes | 109/L | 0.44 | 0.72 | 0.54 | 0.2–0.8 |
| Monocytes (%) | % | ↑ 11.0 | 6.6 | ↑10.1 | 3.0–8.0 |
| Eosinophils | 109/L | ↑ 0.46 | ↑0.49 | 0.36 | 0.04–0.40 |
| Eosinophils (%) | % | ↑ 11.5 | 4.5 | ↑6.7 | 1.0–5.0 |
| Basophils | 109/L | 0.07 | 0.02 | 0.05 | 0.020–0.100 |
| Basophils (%) | % | ↑ 1.8 | 0.2 | 0.9 | 0.0–1.0 |
| Red blood cells | 1012/L | 4.96 | 4.39 | 5.02 | 4.1–6.2 |
| Hemoglobin | g/dL | 15 | ↓ 13.4 | 15.2 | 14.0–18.0 |
| Hematocrit | % | 42.8 | ↓ 38.0 | 44.2 | 40.0–54.0 |
| Mean corpuscular volume | fL | 86.3 | 86.6 | 88 | 77.0–95.0 |
| Mean corpuscular hemoglobin concentration | g/dL | 35 | 35.3 | 34.4 | 32.0–36.0 |
|
| |||||
| Na | mmol/L | 139.28 | ↓ 135.8 | 140.02 | 136.0–145.0 |
| K | mmol/L | 4.75 | 4.13 | 5.12 | 3.8–5.2 |
| Cl | mmol/L | 99.29 | 98.89 | 101.36 | 98.0–110.0 |
| Protein | g/dL | 7 | / | 6.9 | 6.0–8.0 |
| Glucose | mg/dL | ↑ 105 | ↑109.0 | 95 | 70–99 |
| Creatinine | mg/dL | 0.76 | 0.74 | 0.64 | 0.30–1.20 |
| Estimated glomerular filtration rate | mL/min/1.73 m2 | ≥60 | ≥60 | ≥60 | / |
| Urea | mg/dL | 25 | 35 | 28 | <50 |
| Uric acid | mg/dL | 4.2 | 4.2 | 4.7 | 2.7–7.0 |
| Alanine aminotransferase | U/L | 12.74 | ↑73.65 | 32.96 | <40.0 |
| Aspartate amino transferase | U/L | 18.42 | ↑249.18 | 24.93 | <37.0 |
| Gamma-G glutamyl transpeptidase | U/L | 25.42 | 20.64 | 37 | 6.00–71.00 |
| Amylase | U/L | 51.54 | 47.21 | 56.02 | 10.0–100.0 |
| Creatine kinase | U/L | 102.9 | ↑ 5079.6 | 91.1 | 26–174 |
| Cholesterol | mg/dL | ↑ 255 | 177 | ↑ 240 | 115–190 |
| HDL-C | mg/dL | 67 | 80 | 72 | >40 |
| Triglycerides | mg/dL | 55.04 | 34.9 | 82.81 | <150.0 |
| Low-density lipoprotein direct measured | mg/dL | 185 | 106 | 163 | <115 |
| Non-HDL-C | mg/dL | 188 | 97 | 168 | 40–160 |
| Fe | µg/dL | 120 | 70 | 134 | 70–181 |
| Unsaturated iron binding capacity | ug/dL | 193.9 | 179 | 197.3 | 150.0–349.0 |
| Transferrin saturation | % | 39.75 | 29.27 | 40.69 | 20.00–45.00 |
| Total iron binding capacity | µg/dL | 321.85 | 253.07 | 332.68 | 200–400 |
| C-reactive protein | mg/L | 0.09 | ↑144.12 | 1.52 | 0.0–5.0 |
| D-Dimers | ng/mL | 352.84 | 398.09 | 277.3 | <113.0 |
| N-terminal-pro hormone BNP | pg/mL | 9.9 | 213.6 | 16.1 | <125.00 |
| Troponin T | pg/mL | 3.67 | 8.11 | 6.32 | <14 |
| BNP | pg/mL | / | 29 | <2 | <35 |
|
| |||||
| Activated partial thromboplastin time | sek. | 23.9 | 33 | 28.7 | / |
| Activated partial thromboplastin time ratio | / | ↓0.70 | 0.97 | 0.84 | 0.80–1.20 |
| Prothrombin time | sek. | 10.1 | 10.4 | 9.5 | / |
| Prothrombin ratio | % | 101 | 98 | 107 | 80.0–120.0 |
| International normalized ratio | / | 0.99 | 1.02 | 0.93 | 0.80–1.20 |
| Fibrinogen | g/L | 3.7 | ↑ 8.24 | ↑ 4.26 | 1.80–4.00 |
BNP, brain natriuretic protein; HDL-C, high-density lipoprotein cholesterol, ↓- under the reference values, ↑ - above the reference values.
Electrocardiography parameters.
| Parameters | Units | Before Run | 1 Day after the Run | 10 Days after the Run |
|---|---|---|---|---|
| Rhythm | / | Sinus, 74’ | Sinus, 75’ | Sinus, 78’ |
| PQ duration | ms | 160 | 140 | 160 |
| The length of PII | ms | 120 | 100 | 120 |
| P V1 negative deflection amplitude | mm | 1 | 1.5 | 1 |
| QRS duration | ms | 100 | 100 | 96 |
| rSr’ (leads where present) | / | V1-V2 | V1-V2 | V1-V2 |
| QRS morphology | / | rSr’ V1-V2 | rSr’ V1-V2 | rSr’ V1-V2 |
| QRS voltage criteria for left ventricular hypertrophy SV1 + RV5 or RV6 >3.5 mV (35 mm) | mm | 32/16? | 32/16 | 32/16 |
| QRS voltage criteria for right ventricular hypertrophy RV1 + SV5 or SV6 >1.1 mV (11 mm) | mm | 5.0/1? | 4.5/1 | 4.5/1 |
| QTc duration | ms | 410 | 440 | 420 |
| T negative (leads when present) | / | III, aVF, V1, V2 | III, V1, V2 | III, aVF, V1, V2 |
Figure 2(A) ECG: before the run. (B). ECG: 1 day after the run. (C). ECG: 10 days after the run.
Heart systolic and diastolic function in echocardiographic parameters.
| Parameters | Units (Normal Values) | Before the Run | 1 Day after the Run | 10 Days after the Run |
|---|---|---|---|---|
| Left ventricle end-diastolic diameter volume | mL (106 ± 22) | 109 | 126 | 113 |
| Left ventricle end-systolic diameter volume | mL (41 ± 10) | 33 | 35 | 33 |
| Ejection fraction 2D (%) bi-plane | % (62 ± 5) | 70 | 72 | 71 |
| Global longitudinal strain | % (−20) | 20.3 | 21.9 | 20.3 |
| Interventricular septum diameter | mm (6–10) | 9 | 10 | 10 |
| Posterior wall diastolic diameter | mm (6–10) | 9 | 9 | 9 |
| Right ventricular end-diastolic diameter | mm (20–30) | 31 | 34 | 29 |
| S’ right ventricle | cm/s (14.1 ± 2.3) | 16 | 14 | 17 |
| Left atrium | mm (30–40) | 33 | 36 | 34 |
| Left atrial volume index | mL/m2 (16–34) | 31.8 | 32.3 | 33.5 |
| Right atrial area | cm2 (16 ± 5) | 17.4 | 20.7 | 18.7 |
| Mitral valve E-wave | cm/s (73 ± 19) | 87 | 75 | 75 |
| Mitral valve A-wave | cm/s (69 ± 17) | 50 | 57 | 46 |
| E’ lateral | cm/s (>10) | 21 | 21 | 20 |
| E’ septal | cm/s (>7) | 14 | 12 | 12 |
| E/e’ lateral | ratio (<15) | 4.1 | 3.5 | 3.8 |
| E/e’ septal | ratio (<13) | 6.2 | 6.3 | 6.2 |
Magnetic resonance imaging parameters.
| Parameters | Units | Before the Run | 1 Day after the Run | 10 Days after the Run | Reference Values |
|---|---|---|---|---|---|
| Left atrium (4CH) | cm2 | 23 | 24 | 23 | 15–29 |
| LV ejection fraction | % | 73 | 73 | 73 | 57–75 |
| LV stroke volume | mL | 102 | 107 | 104 | 79–135 |
| LV end-diastolic volume index | mL/m2 | 79 | 83 | 80 | 66–101 |
| LV end-systolic volume index | mL/m2 | 22 | 23 | 22 | 18–39 |
| LV systolic volume index | mL/m2 | 57.6 | 60 | 58.5 | 43–67 |
| LV end-diastolic volume | mL | 140 | 148 | 142 | 121–204 |
| LV end-systolic volume | mL | 38 | 41 | 38 | 33–78 |
| LV mass | g | 182 | 182 | 182 | 109–185 |
| Interventricular septal end diastole | mm | 10 | 10 | 10 | 6.0–10.4 |
| Cardiac output | L/min | 7.1 | 7.2 | 7.3 | 2.8–8.8 |
| Right atrium (4CH) | cm2 | 25 | 28 | 25 | 14–30 |
| RV ejection fraction | % | 60 | 63 | 62 | 50–76 |
| RV stroke volume | mL | 101 | 107 | 105 | 74–142 |
| RV end-diastolic volume index | mL/m2 | 96 | 96.4 | 95.5 | 65–111 |
| RV end-systolic volume index | mL/m2 | 39 | 36 | 36 | 18–47 |
| RV systolic volume index | mL/m2 | 57.5 | 60.5 | 59 | 39–71 |
| RV end-diastolic volume | mL | 170 | 171 | 170 | 121–221 |
| RV end-systolic volume | mL | 69 | 64 | 65 | 34–94 |
| Heart rate | bpm | 70 | 67 | 70 | 60–90 |
| Myocardial contraction disorders | / | no | no | no | / |
| Perfusion disorders | / | no | no | no | / |
| Delayed myocardial enhancement | / | no | no | no | / |
| Tricuspid valve regurgitation | / | + mild | + mild | + mild | / |
| Myocardial edema on T2-weighted magnetic resonance imaging | / | no | no | no | / |
LV, left ventricle/left ventricular; RV, right ventricle/right ventricular.
The ratio of phosphocreatine (PCr) to adenosine triphosphate (ATP) in the interventricular septum on particular days.
|
|
|
|
|
|
| PCr | 5.22 | 6.27 | 7.34 | 6.27 |
| ATP | 4.22 | 4.46 | 4.89 | 4.38 |
| PCr/ATP | 1.24 | 1.4 | 1.5 | 1.43 |
|
|
|
|
|
|
| PCr | 6.4 | 4.24 | 3.99 | 4.87 |
| ATP | 4.42 | 4.53 | 2.58 | 3.84 |
| PCr/ATP | 1.45 | 0.94 | 1.54 | 1.26 |
|
|
|
|
|
|
| PCr | 5.06 | 6.44 | 5.02 | 5.49 |
| ATP | 3.55 | 3.36 | 3.05 | 3.32 |
| PCr/ATP | 1.43 | 1.91 | 1.64 | 1.65 |
ATP, adenosine triphosphate; IVS, interventricular septum; PCr, phosphocreatine.
Figure 3Cardiac-gated 2D CSI 31P spectra from the interventricular septum obtained: (A) before the run; (B) 2 days after the run; and (C) 11 days after the run.